Extension Study for the Port Delivery System With Ranibizumab (Portal)

Inclusion Criteria:

• Previous enrollment in and completion of Study GX28228 (Ladder) or Study GR40548 (Archway), without early treatment or study discontinuation in either study ORPrevious enrollment in Study WR42221 (Velodrome) and either not eligible to berandomized in Study WR42221 at Week 24 or completed the study (from the Q24W or Q36Warm)

• Ability and willingness to undertake all scheduled visits and assessments

• For women of childbearing potential: agreement to remain abstinent or usecontraceptive measures

Exclusion Criteria:

• Pregnant or breastfeeding, or intending to become pregnant during the treatmentperiod and for at least 28 days after the last intravitreal injection of ranibizumabor 1 year after the last Implant refill-exchange of ranibizumab

• History of other ocular diseases that give reasonable suspicion of a disease orcondition that contraindicates the use of ranibizumab, that might affectinterpretation of the results of the study or that renders the participant at highrisk for treatment complications

• History of other diseases, metabolic dysfunction, or clinical laboratory findinggiving reasonable suspicion of a disease or condition that contraindicates the useof ranibizumab or placement of the Implant and that might affect interpretation ofthe results of the study or that renders the participant at high risk of treatmentcomplications

• Requirement for continuous use of any medications or treatments indicated in the "Prohibited Therapy"

Sub-study 1

Inclusion Criteria

• For women of childbearing potential: agreement to remain abstinent (refrain fromheterosexual intercourse) or use contraceptive measures

Participants must meet the following ocular criteria for the study eye for substudy entry:

• Diagnosis of exudative nAMD within 2 years prior to the enrollment visit

• Previous treatment with at least two anti-VEGF ITV injections (e.g., ranibizumab,bevacizumab, or aflibercept) for nAMD per standard of care within 6 months prior tothe enrollment visit

• Demonstrated response to prior anti-VEGF ITV treatment since diagnosis, as evidencedat enrollment by the following:

Overall decrease in nAMD disease activity detected on SD-OCT AND Stable or improved best-corrected visual acuity (BCVA)

• All subtypes of nAMD lesions are permissible (i.e., type I, type II, type III, ormixed forms per optical coherence tomography (OCT) classification) nAMD lesions atthe time of diagnosis must involve the macula (6 mm diameter centered at the fovea).

• Sufficiently clear ocular media and adequate pupillary dilation to allow foranalysis and grading by the central reading center of FP and SD-OCT images.

Exclusion Criteria Prior Ocular Treatments Study Eye

• History of vitrectomy surgery, submacular surgery, or other surgical interventionfor AMD

• Prior treatment with Visudyne, external-beam radiation therapy, or transpupillarythermotherapy

• Previous treatment with corticosteroid ITV injection

• Previous intraocular device implantation

• Previous laser (any type) used for AMD treatment

Either Eye

• Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to theenrollment visit

• Prior participation in a clinical trial involving anti-VEGF drugs within 6 monthsprior to the enrollment visit, other than ranibizumab

CNV Lesion Charateristics Study Eye

• Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage isgreater than 0.5 disc area (1.27 mm2 ) in size at screening

• Subfoveal fibrosis or subfoveal atrophy

Either Eye

• CNV due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia

Concurrent Ocular Conditions Study Eye

• Retinal pigment epithelial tear

• Any concurrent intraocular condition (e.g., cataract, glaucoma, diabeticretinopathy, or epiretinal membrane) that would either require surgical interventionduring the study to prevent or treat visual loss that might result from thatcondition or affect interpretation of study results

• Active intraocular inflammation (grade trace or above)

• History of vitreous hemorrhage

• History of rhegmatogenous retinal detachment

• History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 monthsprior to the enrollment visit

• Aphakia or absence of the posterior capsule

• Previous violation of the posterior capsule is also an exclusion criterion unless itoccurred as a result of yttrium-aluminum garnet (YAG) laser posterior capsulotomy inassociation with prior, posterior chamber intraocular lens implantation.

• Spherical equivalent of the refractive error demonstrating more than 8 diopters ofmyopia

• Preoperative refractive error that exceeds 8 diopters of myopia, for participantswho have undergone prior refractive or cataract surgery in the study eye

• Intraocular surgery (including cataract surgery) within 3 months preceding theenrollment visit

• Uncontrolled ocular hypertension or glaucoma and any such condition the investigatordetermines may require a glaucoma-filtering surgery during a patient's participationin the study

• History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucomasurgery

• History of corneal transplant

• History of prior vitrectomy surgery and absence of posterior capsule

Either Eye

• History of idiopathic or autoimmune-associated uveitis

• Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis

Concurrent Systemic Conditions

• Inability to comply with study schedule or procedures as described in the studyprotocol

• Uncontrolled blood pressure

• History of stroke within the last 3 months prior to informed consent

• Uncontrolled atrial fibrillation within 3 months of informed consent

• History of myocardial infarction within the last 3 months prior to informed consent

• History of other disease, metabolic dysfunction, or clinical laboratory findinggiving reasonable suspicion of a disease or condition that contraindicates the useof ranibizumab or placement of the implant and that might affect interpretation ofthe results of the study or renders the patient at high risk of treatmentcomplications in the opinion of the investigator

• Current systemic treatment for a confirmed active systemic infection

• Use of any systemic anti-VEGF agents

• Chronic use of oral corticosteroids

• Active cancer within 12 months of enrollment

• Previous participation in any non-ocular (systemic) disease studies ofinvestigational drugs within 1 month preceding the informed consent (excludingvitamins and minerals)

• Use of antimitotic or antimetabolite therapy within 30 days or 5 eliminationhalf-lives of the enrollment visit

• History of albinism

• Pregnant or breastfeeding, or intending to become pregnant during the treatmentperiod and for at least 28 days after the last ITV injection of ranibizumab or 1year after the last implant refill-exchange of ranibizumab

Sub-study 2

Inclusion Criteria:

• Having experienced septum dislodgement in the original implant while in the mainstudy or after exiting the main study Ocular Inclusion Criteria for Study Eye

• Sufficiently clear ocular media and adequate pupillary dilation to allow foranalysis and grading by central reading center

Exclusion Criteria (Cohort 1 only):

Concurrent Ocular Conditions-Study Eye

• Any ocular condition that may render the patient at high risk for surgical ortreatment complications

• Intraocular surgery (including cataract surgery) within 1 month preceding theenrollment visit

• Any use of medicated intraocular implants (other than the PDS implant), at any timeprior to enrollment

• History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 monthsprior to the enrollment visit

• Any concurrent ocular condition that would require surgical intervention during thestudy to prevent or treat visual loss

• Concurrent conjunctival, Tenon's capsule, and/or scleral condition in thesupero-temporal quadrant of the eye (e.g., scarring, thinning, mass) that may affectthe refill-exchange procedure of the PDS implant

• Ongoing ocular complications that might affect participant safety

Concurrent Ocular Conditions-Either Eye

• Suspected or active ocular or periocular infection

• Any history of uveitis

• Active blepharitis

Concurrent Systemic Conditions

• Recent history (in the last 3 months prior to enrollment) of other disease, othernon-diabetic metabolic dysfunction, physical examination finding, or clinicallaboratory finding giving reasonable suspicion of a condition that contraindicatesthe use of ranibizumab or surgical placement of the PDS implant; that might affectinterpretation of the results of the study; or that renders the participant at highrisk for treatment complications

• Active cancer within the last 12 months, except for appropriately treated carcinomain situ of the cervix, non-melanoma skin carcinoma, or prostate cancer

• Current systemic treatment for a confirmed active systemic infection - Participationin an investigational trial that involves treatment with any drug or device (withthe exception of vitamins and minerals or enrollment in the main study GR40549)within 6 months prior to enrollment.

• Use of antimitotic or antimetabolite therapy within 30 days or 5 eliminationhalf-lives.